Piperidine urea derivatives for obesity therapy
AssigneeAstrizi Bio, Inc.
InventorsIsh Khanna, Sivaram Pillarisetti, Hans Marcus Malkmus, Kathrin Christin Kortschak
Life of this patent
Estimating the term…
Abstract
The subject matter disclosed herein is generally directed to methods and compositions for preventing, suppressing or treating obesity and/or obesity-induced disorders, specifically, select piperidine urea-derived compounds as a monotherapy or a combination therapy with glucagon-like peptide 1 (GLP-1—SEQ ID NO: 1) receptor agonist and/or dual GLP-1 (SEQ ID NO: 1) and glucose-dependent insulinotropic polypeptide GIP (SEQ ID NO: 8) receptor agonist for the treatment of obesity.
Claims23
A method of treating obesity and/or obesity-induced disorder(s) comprising:
- administrating to a subject a therapeutic amount of at least one compound of Formula I:
- where
- R1 is selected from a group consisting of alkyl, hydrogen, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl and wherein when R1 is aryl, heteroaryl or heterocycloalkyl, R1 is unsubstituted or substituted with alkyl, hydroxy, halogen, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, amine, SO2NHR2, or COR3;
- R2 is selected from a group consisting of hydrogen, alkyl, haloalkyl, or cycloalkyl;
- R3 is selected from a group consisting of alkyl, cycloalkyl, hydroxy, amine, alkyamine or alkoxy;
- R4 is selected from a group consisting of hydrogen, alkyl, halogen, haloalkyl, hydroxy, amine, alkoxy, SO2R5, or COR3;
- R5 is selected from a group consisting of alkyl, haloalkyl, cycloalkyl, aryl or amine;
- R6 is selected from a group consisting of alkyl, cycloalkyl, aryl or heteroaryl;
- X is selected from O, (CH2)p, NH and p is from 0-2;
- Y1-Y2 are selected from CH—CH2, CH—O, or C═CH, however when Y1-Y2 is CH—O, X is selected from O or NH or R1 is not hydrogen;
- and
- Y3 is selected from H or Me,
- its stereoisomers or pharmaceutically acceptable salts thereof.
A method of treating obesity comprising administering to a subject a therapeutic amount of a SEQ ID NO:
- 2 inhibitor along with therapeutic amount of at least one further compound which is selected from at least one SEQ ID NO:
- 1 receptor agonist, at least one glucose-dependent insulinotropic polypeptide receptor agonist or at least one dual SEQ ID NO:
- 1 and SEQ ID NO:
- 8 receptor agonist.
A method of preventing or treating obesity and obesity-induced disorders such as insulin resistance and metabolic syndrome, the method comprising administering to a subject a therapeutic amount of a SEQ ID NO:
- 2 inhibitor along with therapeutic amount of at least one further compound which is selected from at least one SEQ ID NO:
- 1 receptor agonist, at least one glucose-dependent insulinotropic polypeptide receptor agonist or at least one dual SEQ ID NO:
- 1 and SEQ ID NO:
- 8 receptor agonist.
Dependencies are inferred from the claim text.